Education
About Us
Working with TipRanks
Follow Us
Biophytis (BPTSY)
OTHER OTC:BPTSY
BPTSY Stock Chart & Stats
$0.74
-$1.35(-31.02%)
At close: 4:00 PM EST
$0.74
-$1.35(-31.02%)
Day’s Range― - ―
52-Week Range$0.67 - $3.53
Previous CloseN/A
Volume804.00
Average Volume (3M)52.00
Market Cap
$2.82M
Enterprise Value$7.88M
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$9.12M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Feb 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding4,211,828
10 Day Avg. Volume88
30 Day Avg. Volume52
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.60
Price to Sales (P/S)0.00
P/FCF Ratio-1.79
Enterprise Value/Market Cap2.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-34.84
Enterprise Value/Ebitda-1.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biophytis News
BPTSY FAQ
What was Biophytis’s price range in the past 12 months?
Biophytis lowest stock price was $0.67 and its highest was $3.53 in the past 12 months.
What is Biophytis’s market cap?
Biophytis’s market cap is $2.82M.
When is Biophytis’s upcoming earnings report date?
Biophytis’s upcoming earnings report date is Feb 23, 2026 which is in 8 days.
How were Biophytis’s earnings last quarter?
Biophytis released its earnings results on Nov 04, 2025. The company reported -$1.962 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.962.
Is Biophytis overvalued?
According to Wall Street analysts Biophytis’s price is currently Overvalued.
Does Biophytis pay dividends?
Biophytis does not currently pay dividends.
What is Biophytis’s EPS estimate?
Biophytis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biophytis have?
Biophytis has 4,211,828 shares outstanding.
What happened to Biophytis’s price movement after its last earnings report?
Biophytis reported an EPS of -$1.962 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.55%.
Which hedge fund is a major shareholder of Biophytis?
Currently, no hedge funds are holding shares in BPTSY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biophytis
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Technical Analysis
Oragenics
―
InMed Pharmaceuticals
―
Pasithea Therapeutics Corp
―
SciSparc Ltd.
―
Onconetix
―